Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: semi_infinite who wrote (739)	1/6/2005 4:46:59 PM
From: tuck	Respond to of 897

Studies by them say no problem there. But the problem that got ARDM, night-time glucose levels, wasn't measured in those studies, to my knowledge. Frustratingly, I haven't heard what Novo figured out from analyzing said problem -- but they bought the rights to the program from ARMD recently. See here and the ARDM thread for details. Seems as though EMEA has been sitting on the European NDA for a long time; I've heard a vague rumor -- mentioned here -- that there might be a problem with it. Meanwhile Pfizer's target date for an FDA NDA is sometime this year. Bottom line? Bearish, but not with sufficient conviction. Cheers, Tuck